Psilocybin Therapy Shows Positive Phase 3 Results for Treatment-Resistant Depression
Compass Pathways reported positive results from Phase 3 trials of COMP360, a synthetic psilocybin treatment for depression, potentially making it the first psilocybin-based medication approved in the U.S.